Demonstrating clinically meaningful benefit in broad population of patients with early breast cancer Ribociclib plus endocrine therapy (ET) significantly reduced
Novartis NATALEE trial meets primary endpoint tribune.net.ph - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tribune.net.ph Daily Mail and Mail on Sunday newspapers.
Patients with HR+/HER2- early breast cancer treated with the CDK4/6 inhibitor plus endocrine therapy in the phase 3 NATALEE trial had a reduced risk for the cancer to recur.
Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is the.